Huons Meditech celebrated the inauguration of its complete knock down (CKD) production line for endoscope disinfectors on Monday in Hyderabad, Telangana, India, in partnership with the Vasu Group, the company announced on Tuesday.
Yoon Seong-tae, Chairman of Huons Group, was present at the ceremony. Executives and staff from both Huons Meditech and the Vasu Group convened to discuss future strategies and strengthen their collaborative efforts.
Founded in 1985, the Vasu Group is a prominent Indian distributor of pharmaceuticals and medical devices. The company operates a manufacturing facility in Hyderabad, a key hub for India’s medical device industry. Huons Meditech inked a deal with the Vasu Group last March to penetrate the Indian market, focusing on component exports for local assembly under the CKD model.
The endoscope disinfectors manufactured using the CKD method will enjoy local production benefits in India and be distributed nationwide. This strategy aims to bolster Huons Meditech’s price competitiveness and enhance its brand recognition across India.
To ensure smooth CKD production in India, Vasu Group engineers underwent training at Huons Meditech’s headquarters in Korea last month, focusing on CKD production techniques and quality control measures. The training program was designed to facilitate technology transfer and establish robust quality standards for CKD production.
Subsequently, on February 20, Huons Meditech personnel visited the Vasu Group’s production facility in Hyderabad to inspect the CKD production line for endoscope disinfectors and provide additional training.
Through this local production partnership with the Vasu Group, Huons Meditech anticipates significant benefits, including improved price competitiveness, optimized logistics, and accelerated expansion into global markets.
The company also plans to broaden its CKD product range, starting with endoscope disinfectors and expanding to include extracorporeal shock wave lithotripters and disinfectants, as part of its strategy to rapidly penetrate the Indian market.
Ha Chang-woo, Chief Executive Officer (CEO) of Huons Meditech, remarked that this inauguration ceremony marks a pivotal moment for both companies to foster mutual growth through strategic collaboration. He added that the establishment of this CKD production line represents the foundation of our localization strategy and will serve as a key driver for Huons Meditech’s global expansion efforts this year.